Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2018-03-07 Capital/Financing Update
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 7, 2018, announcing that 'Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement'. This explicitly details a financing activity where the company secured capital through the placement of Convertible Bonds (CBs). This directly aligns with the definition of 'Capital/Financing Update' (Code: CAP), which covers updates on company fundraising and financing activities.
2018-03-07 English
Bone Therapeutics collecte 19,45 M€ d’engagements dans le cadre d’un placement d’obligations convertibles
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 7, 2018, announcing that Bone Therapeutics has successfully raised €19.45 million through a private placement of convertible bonds ('obligations convertibles'). The content details the financing amount, the intended use of proceeds (funding clinical trials and operations), and the terms of the convertible bonds and warrants. This clearly falls under the category of updates on company fundraising and capital structure changes. This matches the definition for Capital/Financing Update (CAP). It is not an Earnings Release (ER) as it focuses on financing, nor is it a full Annual Report (10-K) or Interim Report (IR).
2018-03-07 French
Bone Therapeutics Announces Private Placement of Convertible Bonds
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 7, 2018, titled "Bone Therapeutics Announces Private Placement of Convertible Bonds." This announcement details a financing activity—the private placement of senior, unsecured convertible bonds (CBs). This directly corresponds to the definition of Capital/Financing Update (CAP), which covers company fundraising and financing activities.
2018-03-07 English
Bone Therapeutics annonce un placement privé sous forme d’obligations convertibles
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 7, 2018, titled "Bone Therapeutics annonce un placement privé sous forme d'obligations convertibles" (Bone Therapeutics announces a private placement in the form of convertible bonds). This announcement details a financing activity—the issuance of convertible bonds via an accelerated book-building process. This directly corresponds to the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and capital structure changes. It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate finance action.
2018-03-07 French
Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman
Board/Management Information Classification · 99% confidence The document is a press release dated February 20, 2018, announcing a significant change in the company's leadership: the appointment of Jean Stéphenne as Chairman of the Board of Directors, replacing Steve Swinson. This directly relates to changes in the governing body of the company. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The content is a formal announcement of a board change, not a full financial report (10-K, IR) or a general regulatory filing (RNS).
2018-02-20 English
Bone Therapeutics annonce le renforcement de son Conseil d’administration avec la nomination de Jean Stéphenne en tant que Président
Board/Management Information Classification · 99% confidence The document is titled "Information réglementée" (Regulated Information) and announces a significant change in corporate governance: the appointment of Jean Stéphenne as Chairman of the Board of Directors and the departure of the previous chairman. This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific management event.
2018-02-20 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.